Association of antiagregants: when and how

• Published in: Medicina clínica Vol. 128; no. 10; p. 383
• Main Authors: López Menchaca, Ramiro, Herrero Martínez, Juan María, Suárez Fernández, Carmen
• Format: Journal Article
• Language: Spanish
• Published: Spain 17-03-2007
• Subjects: Atherosclerosis - complications; Atrial Fibrillation - complications; Cerebrovascular Disorders - drug therapy; Coronary Disease - drug therapy; Cost-Benefit Analysis; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Hemorrhage - chemically induced; Humans; Peripheral Vascular Diseases - drug therapy; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - classification; Platelet Aggregation Inhibitors - economics; Platelet Aggregation Inhibitors - therapeutic use; Risk Assessment; Thromboembolism - etiology; Thromboembolism - prevention & control; Thrombophilia - complications; Thrombophilia - drug therapy; Thrombophilia - etiology
• ISSN: 0025-7753
• DOI: 10.1157/13099977

Aterothrombotic disease (coronary, cerebrovascular and peripheral artery disease) is the most common cause of mortality and disability in the world, antiaggregants representing one of its therapeutic and preventive pillars. We have drugs at present that act at different levels of platelet aggregation (COX inhibitors as well as inhibitors of phosphodiesterase, ADP P2Y12 receptor and IIb/IIIa receptor). We review here the efficacy and safety of the association of antiaggregants in most relevant clinical scenarios, including current clinical recommendations and an analysis of supportive evidence.